C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis.

J Eur Acad Dermatol Venereol

Department of Dermatology, University Medical School of Lublin, Radziwiłłowska 13, 20-250 Lublin, Poland.

Published: March 2004

Background: An acute phase of psoriasis can be induced by cytokines involved in psoriatic pathogenic phenomena. Activation of the acute phase reaction by proinflammatory cytokines (including interleukins 1 and 6, tumour necrosis factor alpha) may account for systemic symptoms in severe psoriasis, especially in pustular and arthropathic forms of this disease.

Objective: To study the activity of selected acute phase proteins in psoriatics before and after effective treatment.

Method: Plasma concentrations of C-reactive protein (CRP) and alpha2-macroglobulin (alpha2-MG) were examined in 175 males with medium-severe and severe psoriasis in the active stage, before treatment and in remission achieved with various treatments (local, acitretin, psoralen + ultraviolet A, retinoid + psoralen + UVA [Re-PUVA] methotrexate, cyclosporin A). Clinical activity of psoriasis was evaluated using the Psoriasis Area and Severity Index score, ranging from 18 to 70.8 (mean 29.2). Measurements were done using the immunoenzymatic method. The control group consisted of 30 healthy male volunteers.

Results: In the active stage of disease highly increased plasma levels of both CRP and alpha2-MG were found (P < 0.001). It appeared that efficacious treatment was correlated with a considerable decrease of the proteins examined towards the control values. Mean levels of alpha2-MG after treatment did not differ significantly from those of controls (P > 0.15). However, despite their strong decrease following all methods of treatment, mean plasma levels of CRP remained significantly elevated during remission compared with those of the healthy controls (P < 0.001).

Conclusions: The results of this study indicate that in medium-severe and severe psoriasis the acute phase response can be initiated and is not completely extinguished in phases of clinical remission.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1468-3083.2004.00863.xDOI Listing

Publication Analysis

Top Keywords

severe psoriasis
16
acute phase
16
medium-severe severe
12
c-reactive protein
8
active stage
8
plasma levels
8
levels crp
8
psoriasis
7
protein alpha2-macroglobulin
4
plasma
4

Similar Publications

Background: Psoriasis is an inflammatory disease primarily treated through molecular-targeted therapies. However, emerging evidence suggests that dietary interventions may also play a role in managing inflammation associated with this condition. The Mediterranean diet (MedDiet), prevalent in southern European countries, has been widely recognized for its ability to reduce cardiovascular mortality, largely due to its anti-inflammatory properties.

View Article and Find Full Text PDF

Successful Treatment of Severe Dystrophic Nail Psoriasis With Deucravacitinib.

Cutis

December 2024

Department of Dermatology, State University of New York, Downstate Health Sciences University, Brooklyn. Jennifer Wang and Dr. Jagdeo also are from the Dermatology Service, Veterans Affairs New York Harbor Healthcare System, Brooklyn. Dr. Derrick also is from NYC Health + Hospitals/Kings County, Brooklyn.

View Article and Find Full Text PDF

Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.

Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.

View Article and Find Full Text PDF

Introduction: Neutrophil gelatinase-associated lipocalin (NGAL) is believed to be involved in the pathogenesis of psoriasis, and its serum level was previously found to decline after administration of biologics, UV, and cyclosporine therapy.

Aim: To investigate whether NGAL may serve as a biomarker of disease activity in psoriasis vulgaris.

Material And Methods: To measure the level of NGAL in serum, 36 patients with psoriasis vulgaris and 33 healthy controls were enrolled.

View Article and Find Full Text PDF

Tanshinone I Ameliorates Psoriasis-Like Dermatitis by Suppressing Inflammation and Regulating Keratinocyte Differentiation.

Drug Des Devel Ther

January 2025

Department of Dermatology, Second Xiangya Hospital, Hunan Key Laboratory of Medical Epigenomics, Clinical Medical Research Center of Major Skin Diseases and Skin Health of Hunan Province, Central South University, Changsha, Hunan, People's Republic of China.

Background: Psoriasis is an immune-related inflammatory systemic condition characterized by dysregulated keratinocyte proliferation and chronic inflammation. Tanshinone I (Tan-I) has recently been discovered to have immunomodulatory properties, but its role and mechanisms in treating psoriasis remain unclear.

Objective: To evaluate the efficacy of Tan-I in the treatment of psoriasis and to determine the mechanisms involved.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!